C. Guaza

Publications201
h-index53
Citations8,921
Highly Influential Citations413
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • J. Fernández-Ruiz
  • 323 Publications • 17,743 Citations
  • L. Mestre
  • 68 Publications • 2,500 Citations
  • V. Di Marzo
  • 645 Publications • 53,765 Citations
  • R. Mechoulam
  • 564 Publications • 48,738 Citations
  • Publications
  • Influence
Prenatal Immune Challenge Disrupts Sensorimotor Gating in Adult Rats: Implications for the Etiopathogenesis of Schizophrenia
View on Nature
Therapeutic Action of Cannabinoids in a Murine Model of Multiple Sclerosis
TLDR
Treatment with the synthetic cannabinoids WIN 55,212–2, ACEA, and JWH-015 during established disease significantly improved the neurological deficits in a long-lasting way and the possible involvement of cannabinoid receptor CB2 would enable nonpsychoactive therapy suitable for long-term use.
View on Publisher
Experience‐dependent Facilitating Effect of Corticosterone on Spatial Memory Formation in the Water Maze
TLDR
This work indicates a facilitating corticosterone action, during the post‐training period, on the neural mechanisms determining the strength of information storage under acute, physiological conditions.
View on Wiley
Ontogeny of sensorimotor gating and immune impairment induced by prenatal immune challenge in rats: implications for the etiopathology of schizophrenia
TLDR
It is shown that prenatal LPS administration throughout pregnancy causes maturation-dependent PPI deficits and age-dependent alterations in dopamine activity, as well as in synaptophysin expression and cytokine levels.
View on Nature
Pharmacological modulation of the endocannabinoid system in a viral model of multiple sclerosis
TLDR
OMDM1 and OMDM2 provide an effective therapy for Theiler murine encephalomyelitis virus‐induced demyelinating disease (TMEV‐IDD) and point to the manipulation of the endocannabinoid system as a possible strategy to develop future MS therapeutic drugs.
View on Wiley
Cannabinoids Promote Oligodendrocyte Progenitor Survival: Involvement of Cannabinoid Receptors and Phosphatidylinositol-3 Kinase/Akt Signaling
TLDR
Oligodendrocyte progenitors undergo apoptosis with the withdrawal of trophic support, and both the selective CB1 agonist arachidonyl-2′-chloroethylamide/(all Z)-N-(2-cycloethyl)-5,8,11,14-eicosatetraenamide and the nonselective cannabinoid agonists HU210 and (+)-Win-55212-2 enhanced cell survival.
View on Publisher
Endogenous Interleukin-1 Receptor Antagonist Mediates Anti-Inflammatory and Neuroprotective Actions of Cannabinoids in Neurons and Glia
TLDR
It is reported for the first time that both CB1 and CB2 receptors modulate release of endogenous IL-1ra from primary cultured glial cells, and this data suggest a novel neuroprotective mechanism of action for CBs in response to inflammatory or excitotoxic insults.
View on Publisher
Activation of the endocannabinoid system as a therapeutic approach in a murine model of multiple sclerosis
TLDR
The results indicate that treatment during established disease significantly improves the motor function of the diseased mice and suggest that agents able to activate the endocannabinoid system could constitute a new series of drugs for the treatment of MS.
View on Wiley
Anandamide enhances IL‐10 production in activated microglia by targeting CB2 receptors: Roles of ERK1/2, JNK, and NF‐κB
TLDR
By altering the cytokine network, AEA could indirectly modify the type of immune responses within the central nervous system (CNS) and pharmacological modulation of AEA uptake and degradation might be a useful tool for treating neuroinflammatory diseases.
View on Wiley
Endocannabinoids drive the acquisition of an alternative phenotype in microglia
View on Elsevier
...
...